Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
130.00    -0.40 (-0.31%)
Bid:
129.60
Ask:
129.80
Spread: 0.20 (0.154%)
Market Cap: £316.44m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director/PDMR Shareholding

13 Nov 2020 17:00

RNS Number : 3174F
PureTech Health PLC
13 November 2020
 

PureTech Health plc (the "Company")

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility or their Connected Persons

 

In connection with the listing of the Company's American Depository Shares ("ADS's") on the Nasdaq Global Market and in order to satisfy Nasdaq listing rules, on 11 November 2020, (i) the Zohar Family Trust I, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to per one ADS and (ii) the Zohar Family Trust II, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to one ADS.

 

The foregoing is a notifiable transaction but does not involve any disposal of such interest. Following this transaction, Ms. Zohar continues to have a direct and indirect interest in 12,197,307 Ordinary Shares, representing approximately 4.3% of the issued share capital of the Company. No Ordinary Shares or ADS's are being sold or disposed of by Ms. Zohar or her related entities in connection with the Nasdaq listing.

 

This notification is made under Article 19 of the Market Abuse Regulation.

 

PDMR DEALING NOTIFICATION

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

The Zohar Family Trust I and The Zohar Family Trust II

2

Reason for the notification

a)

Position/status

Ms. Daphne Zohar, the Chief Executive Officer and a Director, is a Trustee of the above listed Trusts

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of PureTech Health plc

ISIN GB00BY2Z0H74

b)

Nature of the transaction

Conversion by the Zohar Family Trust I of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration and conversion by the Zohar Family Trust II of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Zohar Family Trust I

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

Zohar Family Trust II

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

d)

Aggregated information

-

Aggregated volume

-

Price

 

Price

Aggregate Volume

n/a

n/a

e)

Date of the transaction

11 November 2020

f)

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZXLFFBFLLFBK
Date   Source Headline
21st Jul 202012:02 pmRNSPrice Monitoring Extension
17th Jul 20207:00 amRNSHolding(s) in Company
16th Jul 20201:04 pmRNSVor Appoints Biotech Finance Leader to BOD
14th Jul 20201:04 pmRNSVor Names Oncology Drug Development Expert as CMO
8th Jul 20201:32 pmRNSSonde Launches Voice Health Screening for COVID-19
8th Jul 202012:02 pmRNSPrice Monitoring Extension
7th Jul 202012:03 pmRNSPureTech’s Vor Raises $110M Series B Financing
6th Jul 20207:01 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 20207:00 amRNSTotal Voting Rights
23rd Jun 20201:48 pmRNSKaruna Positive FDA End of Phase 2 Meeting
23rd Jun 20207:00 amRNSAkili Gets European Approval to Market EndeavorRx
22nd Jun 20202:00 pmRNSPRTC Presents New Immuno-oncology Data at AACR
22nd Jun 20207:00 amRNSPDMR Notification RSU Vesting
18th Jun 202012:01 pmRNSGelesis China Deal $35M and up to $388M milestones
16th Jun 20207:00 amRNSAkili Granted FDA Clearance for ADHD Treatment
15th Jun 202012:07 pmRNSSecond Price Monitoring Extn
15th Jun 202012:02 pmRNSPrice Monitoring Extension
12th Jun 202012:08 pmRNSSecond Price Monitoring Extn
12th Jun 202012:03 pmRNSPrice Monitoring Extension
12th Jun 20207:00 amRNSResult of AGM
10th Jun 202012:08 pmRNSSecond Price Monitoring Extn
10th Jun 202012:02 pmRNSPrice Monitoring Extension
9th Jun 20207:00 amRNSPositive Data from Vedanta IBD Clinical Studies
4th Jun 20207:00 amRNSPositive FDA Feedback on Follica
2nd Jun 20207:00 amRNSGelesis Approved to Market Plenity in Europe
28th May 20207:00 amRNSPRTC Targets COVID-19 Post-Recovery Complications
27th May 20207:00 amRNSPRTC to Present at Jefferies Virtual Conference
26th May 20201:05 pmRNSVor Appoints CFO Nathan Jorgensen
26th May 20207:00 amRNSPRTC Receives Another $45M from Affiliate Shares
22nd May 202012:02 pmRNSPrice Monitoring Extension
21st May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
20th May 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
20th May 20207:00 amRNSPDMR Notification – Transfer From Trust
19th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th May 202012:02 pmRNSPrice Monitoring Extension
18th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
15th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
6th May 202012:07 pmRNSSecond Price Monitoring Extn
6th May 202012:02 pmRNSPrice Monitoring Extension
4th May 202012:02 pmRNSPrice Monitoring Extension
23rd Apr 202012:07 pmRNSSecond Price Monitoring Extn
23rd Apr 202012:03 pmRNSPrice Monitoring Extension
22nd Apr 202011:00 amRNSAkili ADHD Treatment Now Available in US
21st Apr 20204:41 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 202012:07 pmRNSSecond Price Monitoring Extn
21st Apr 202012:02 pmRNSPrice Monitoring Extension
14th Apr 20207:00 amRNSPRTC to Present at Virtual Needham Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.